Additive effect of neutralizing antibody and antiviral drug treatment in preventing virus escape and persistence

Journal of Virology

Volumn 74, Issue 13, 2000, Pages 5896-5901

  Seiler, Peter ^a,b   Senn, Beatrice M ^a   Klenerman, Paul ^c   Kalinke, Ulrich ^d   Hengartner, Hans ^a   Zinkernagel, Rolf M ^a  

^a UNIVERSITY OF ZURICH   (Switzerland)

^b MAX PLANCK INSTITUTE FOR INFECTION BIOLOGY   (Germany)

^c JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^d EUROPEAN MOLECULAR BIOLOGY LABORATORY EMBL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; NEUTRALIZING ANTIBODY; RIBAVIRIN;

ANTIBODY RESPONSE; ARTICLE; CYTOPATHOGENIC EFFECT; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNOSURVEILLANCE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PERSISTENT VIRUS INFECTION; PRIORITY JOURNAL; TRANSGENIC MOUSE; VIRUS MENINGITIS;

ANIMALS; ANTIBODIES, VIRAL; ANTIVIRAL AGENTS; BASE SEQUENCE; CELL LINE; CRICETINAE; DNA, VIRAL; FEMALE; IMMUNOGLOBULIN MU-CHAINS; LYMPHOCYTIC CHORIOMENINGITIS; LYMPHOCYTIC CHORIOMENINGITIS VIRUS; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MOLECULAR SEQUENCE DATA; NEUTRALIZATION TESTS; RIBAVIRIN; VARIATION (GENETICS); VIRUS LATENCY;

EID: 0034044681     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.74.13.5896-5901.2000     Document Type: Article

References (62)

1. Adderson, E. E., P. G. Shackelford, R. A. Insel, A. Quinn, P. M. Wilson, and W. L. Carrol. 1992. Immunoglobulin light chain variable region gene sequences for human antibodies to Haemophilus influenzae type b capsular polysaccharide are dominated by a limited number of V kappa and V lambda segments and VJ combinations. J. Clin. Investig. 89:729-738.
2. Adderson, E. E., P. G. Shackelford, A. Quinn, and W. L. Carroll. 1991. Restricted Ig H chain V gene usage in the human antibody response to Haemophilus influenzae type b capsular polysaccharide. J. Immunol. 147: 1667-1674.
3. Adderson, E. E., P. G. Shackelford, A. Quinn, P. M. Wilson, M. W. Cunningham, R. A. Insel, and W. L. Carroll. 1993. Restricted immunoglobulin VH usage and VDJ combinations in the human response to Haemophilus influenzae type b capsular polysaccharide. J. Clin. Investig. 91:2734-2743.
4. Albert, J., B. Abrahamsson, K. Nagy, E. Aurelius, H. Gaines, G. Nystrom, and E. M. Fenyo. 1990. Rapid development of isolate-specific neutralizing antibodies after primary HIV-1 infection and consequent emergence of virus variants which resist neutralization by autologous sera. AIDS 4:107-112.
5. Alberti, A., P. Pontisso, G. Tagariello, D. Cavalletto, L. Chemello, and F. Belussi. 1988. Antibody response to pre-S2 and hepatitis B virus induced liver damage. Lancet i:1421-1424.
6. Amadori, A., P. Gallo, R. Zamarchi, M. L. Veronese, A. DeRossi, D. Wolf, and L. Chieco-Bianchi. 1990. IgG oligoclonal bands in sera of HIV-1 infected patients are mainly directed against HIV-1 determinants. AIDS Res. Hum. Retroviruses 6:581-586.
7. Andrei, W., and E. De Clercq. 1993. Molecular approaches for the treatment of hemorrhagic fever virus infections. Antiviral Res. 22:45-75.
8. Baldridge, J. R., and M. J. Buchmeier. 1992. Mechanisms of antibody-mediated protection against lymphocytic choriomeningitis virus infection: mother-to-baby transfer of humoral protection. J. Virol. 66:4252-4257.
9. Baldridge, J. R., T. S. McGraw, A. Paoletti, and M. J. Buchmeier. 1997. Antibody prevents the establishment of persistent arenavirus infection in synergy with endogenous T cells. J. Virol. 71:755-758.
10. Baldridge, J. R., B. D. Pearce, B. S. Parekh, and M. J. Buchmeier. 1993. Teratogenic effects of neonatal arenavirus infection on the developing rat cerebellum are abrogated by passive immunotherapy. Virology 197:669-677.
11. Battegay, M., S. Cooper, A. Althage, J. Baenziger, H. Hengartner, and R. M. Zinkernagel. 1991. Quantification of lymphocytic choriomeningitis virus with an immunological focus assay in 24 or 96 well plates. J. Virol. Methods 33:191-198.
12. Battegay, M., D. Kyburz, H. Hengartner, and R. M. Zinkernagel. 1993. Enhancement of disease by neutralizing antiviral antibodies in the absence of primed antiviral cytotoxic T cells. Eur. J. Immunol. 23:3236-3241.
13. + T-cell-deficient mice. J. Virol. 68:4700-4704.
14. Battegay, M., D. Moskophidis, H. Waldner, M. A. Bründler, W. P. Fung-Leung, T. W. Mak, H. Hengartner, and R. M. Zinkernagel. 1993. Impairment and delay of neutralizing antiviral antibody responses by virus-specific cytotoxic T cells. J. Immunol. 151:5408-5415.
15. Berberian, L., L. Goodglick, T. J. Kipps, and J. Braun. 1993. Immunoglobulin VH3 gene products: natural ligands for HIV gp 120. Science 261:1588-1591.
16. Bruns, M., J. Cihak, G. Müller, and F. Lehmann-Grube. 1983. Lymphocytic choriomeningitis virus. VI. Isolation of a glycoprotein mediating neutralization. Virology 130:247-251.
17. Chomczynski, P., and N. Sacchi. 1987. Single-step method of RNA isolation by guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem. 162:156-159.
18. Cole, G. A., N. Nathanson, and R. A. Prendergast. 1972. Requirement for theta-bearing cells in lymphocytic choriomeningitis virus-induced central nervous system disease. Nature 238:335-337.
19. D'Amelio, R., R. Biselli, R. Nisini, P. M. Matricardi, A. Aiuti, I. Mezzaroma, E. Pinter, O. Ponteselli, and F. Aiuti. 1992. Spectrotype of anti-gp 120 antibodies remains stable during the course of HIV disease. J. Acquir. Immune Defic. Syndr. 5:930-935.
20. Davenport, F. M., E. Minuse, A. V. Hennessy, and T. J. Francis. 1969. Interpretations of influenza antibody patterns of man. Bull. W. H. O. 41: 453-460.
21. Davis, G. L., R. Esteban-Mur, V. Rustgi, J. Hoefs, S. C. Gordon, C. Trepo, M. L. Shiffman, S. Zeuzem, A. Craxi, M. H. Ling, and J. Albrecht. 1998. Interferon alpha-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. N. Engl. J. Med. 339:1493-1499.
22. Enria, D. A., A. M. Briggiler, S. Levis, D. Vallejos, J. I. Maiztegui, and P. G. Canonico. 1987. Preliminary report: tolerance and antiviral effect of ribavirin in patients with Argentine hemorrhagic fever. Antiviral Res. 7:353-359.
23. Géssner, A., and H. Lother. 1989. Homologous interference of lymphocytic choriomeningitis virus involves a ribavirin-susceptible block in virus replication. J. Virol. 63:1827-1832.
24. Grimaldi, L. M., R. P. Roos, S. G. Devare, W. G. Robey, J. M. Casey, M. E. Gurney, B. R. Apatoff, and D. Lazzarin. 1988. Restricted heterogeneity of antibody to gp 120 and p24 in AIDS. J. Immunol. 141:114-117.
25. Halstead, S. B., and E. J. O'Rourke. 1977. Dengue viruses and mononuclear phagocytes. I. Infection enhancement by non-neutralizing antibody. J. Exp. Med. 146:201-217.
26. Harvie, P., R. F. Omar, N. Dusserre, A. Desormeaux, P. Gourde, M. Tremblay, D. Beauchamp, and M. G. Bergeron. 1996. Antiviral efficacy and toxicity of ribavirin in murine acquired immunodeficiency syndrome model. J. Acquir. Immune Defic. Syndr. 12:451-461.
27. Haynes, B. F., G. Pantaleo, and A. S. Fauci. 1996. Toward an understanding of the correlates of protective immunity to HIV infection. Science 271:324-328.
28. Jahrling, P. B., R. A. Hesse, G. A. Eddy, K. M. Johnson, R. T. Callis, and E. L. Stephen. 1980. Lassa virus infection of rhesus monkeys: pathogenesis and treatment with ribavirin. J. Infect. Dis. 141:580-589.
29. Jahrling, P. B., C. J. Peters, and E. L. Stephen. 1984. Enhanced treatment of lassa fever by immune plasma combined with ribavirin in cynomolgus monkeys. J. Infect. Dis. 149:420-427.
30. Kägi, D., B. Ledermann, K. Bürki, P. Seiler, B. Odermatt, K. J. Olsen, E. Podack, R. M. Zinkernagel, and H. Hengartner. 1994. Cytotoxicity mediated by T cells and natural killer cells is greatly impaired in perforin-deficient mice. Nature 369:31-37.
31. Kalinke, U., E. M. Bucher, B. Ernst, A. Oxenius, H.-P. Roost, S. Geley, R. Kofler, R. Zinkernagel, and H. Hengartner. 1996. The role of somatic mutation in the generation of the protective humoral immune response against vesicular stomatitis virus. Immunity 5:1-20.
32. Kilbourne, E. D. 1977. Influenza pandemics in perspective. JAMA 237:1225-1228.
33. Köhler, H., S. Müller, and P. L. Nara. 1994. Deceptive imprinting in the immune response against HIV-1. Immunol. Today 15:475-478.
34. Koup, R. A., J. T. Safrit, Y. Cao, C. A. Andrews, G. McLeod, W. Borkowsky, C. Farthing, and D. D. Ho. 1994. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J. Virol. 68:4650-4655.
35. Lemon, S. M., and D. L. Thomas. 1997. Vaccines to prevent viral hepatitis. N. Engl. J. Med. 336:196-204.
36. McCormick, J. B., I. J. King, P. A. Webb, C. L. Scribner, R. B. Craven, K. M. Johnson, L. H. Elliott, and R. Belmont-Williams. 1986. Effective therapy with ribavirin. N. Engl. J. Med. 314:20-26.
37. McHutchinson, J. G., S. C. Gordon, E. R. Schiff, M. L. Shiffman, W. M. Lee, V. K. Rustgi, Z. D. Goodman, M. H. Ling, S. Cort, and J. K. Albrecht. 1998. Interferon alpha-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N. Engl. J. Med. 339:1485-1492.
38. Moore, J. P., Y. Cao, D. D. Ho, and R. A. Koup. 1994. Development of the anti-gp120 antibody response during seroconversion to human immunodeficiency virus type 1. J. Virol. 68:5142-5155.
39. + T lymphocytes mediate clearance of virus and regulate the antiviral antibody response. J. Virol. 61:1867-1874.
40. Moskophidis, D., F. Lechner, H. P. Pircher, and R. M. Zinkernagel. 1993. Virus persistence in acutely infected immunocompetent mice by exhaustion of antiviral cytotoxic effector T cells. Nature 362:758-761.
41. Müller, S., H. Wang, G. J. Silverman, G. Bramlet, N. Haigwood, and H. Köhler. 1993. B-cell abnormalities in AIDS: stable and clonally-restricted antibody response in HIV-1 infection. Scand. J. Immunol. 38:327-334.
42. Nowak, M. A., R. M. Anderson, A. R. McLean, T. F. W. Wolfs, J. Goudsmit, and R. M. May. 1991. Antigenic diversity thresholds and the development of AIDS. Science 254:963-969.
43. Planz, O., S. Ehl, E. Furrer, E. Horvath, M.-A. Bründler, H. Hengartner, and R. M. Zinkernagel. 1997. A critical role for neutralizing-antibody-producing B cells, CD4+ T cells, and interferons in persistent and acute infections of mice with lymphocytic choriomeningitis virus: implications for adoptive immunotherapy of virus carriers. Proc. Natl. Acad. Sci. USA 94:6874-6879.
44. Poignard, P., R. Sabbe, G. R. Picchio, M. Wang, R. J. Gulizia, H. Katinger, P. W. H. I. Parren, D. E. Mosier, and D. R. Burton. 1999. Neutralizing antibodies have limited effects an the control of established HIV-1 infection in vivo. Immunity 10:431-438.
45. Poynard, T., P. Marcellin, S. S. Lee, C. Niederau, G. S. Minuk, G. Ideo, V. Bain, J. Heathcote, S. Zeuzem, C. Trepo, and J. Albrecht. 1998. Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 352:1426-1432.
46. Reichard, O., J. Andersson, R. Schvarcz, and O. Weiland. 1991. Ribavirin treatment for chronic hepatitis C. Lancet 337:1058-1061.
47. Reichard, O., G. Norkrans, A. Fryden, J. H. Braconier, A. Sonnerborg, and O. Weiland. 1998. Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. The Swedish Study Group. Lancet 351:83-87.
48. Robert, G. M., M. Brown, and R. C. Gallo. 1985. HTLV-III-neutralizing antibodies in patients with AIDS and AIDS-rclated complex. Nature 316: 72-74.
49. Romanowski, V., Y. Matsuura, and D. H. L. Bishop. 1985. Complete sequence of the S RNA of lymphocytic choriomeningitis virus (WE strain) compared to that of Pichinde arenavirus. Virus Res. 3:101-114.
50. Seiler, P., M.-A. Bründler, C. Zimmermann, D. Weibel, M. Bruns, H. Hengartner, and R. M. Zinkernagel. 1998. Induction of protective cytotoxic T cell responses in the presence of high titers of virus neutralizing antibodies: implications for passive and active immunization. J. Exp. Med. 187:649-654.
51. Seiler, P., U. Kalinke, T. Rülicke, E. M. Bucher, C. Böse, R. M. Zinkernagel, and H. Hengartner. 1998. Enhanced virus clearance by early inducible lymphocytic choriomeningitis virus-neutralizing antibodies in immunoglobulin-transgenic mice. J. Virol. 72:2253-2258.
52. Seiler, P., B. M. Senn, M.-A. Bründler, R. M. Zinkernagel, H. Hengartner, and U. Kalinke. 1999. In vivo selection of neutralization-resistant virus variants, but no evidence for B cell tolerance in lymphocytic choriomeningitis virus-carrier mice expressing a transgenic virus neutralizing antibody. J. Immunol. 162:4536-4541.
53. Sidwell, R. W., J. H. Huffman, D. L. Barnard, D. F. Smee, R. P. Warren, M. A. Chirigos, M. Kende, and J. Huggins. 1994. Antiviral and immunomodulating inhibitors of experimentally-induced Punta Toro virus infection. Antiviral Res. 25:1115-122.
54. Smee, D. F., J. Gilbert, J. A. Leonhardt, B. B. Barnett, J. H. Huggins, and R. W. Sidwell. 1993. Treatment of lethal Pichinde virus infections in weanling LVG/Lak hamsters with ribavirin, ribamidine, selenazofurin, and ampligen. Antiviral Res. 20:57-70.
55. Steiner, I. 1996. Human herpes viruses latent infection in the nervous system. Immunol. Rev. 152:157-173.
56. Thomsen, A. R., J. Johansen, O. Marker, and J. P. Christensen. 1996. Exhaustion of CTL memory and recrudescence of viremia in lymphocytic choriomeningitis virus-infected MHC class II-deficient mice and B cell-deficient mice. J. Immunol. 157:3074-3080.
57. Thomsen, A. R., and O. Marker. 1988. The complementary roles of cellular and humoral immunity in resistance to re-infection with LCM virus. Immunology 65:9-15.
58. Weiss, R. A., P. R. Clapham, P. R. Cheingsong, A. G. Dalgleish, C. A. Carne, I. Weller, and R. S. Tedder. 1985. Neutralization of human T-lymphotropic virus type III by sera of AIDS and AIDS-risk patients. Nature 316:69-71.
59. Wisnewski, A., L. Cavacini, and M. Posner. 1996. Human antibody variable region gene usage in HIV-1 infection. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 11:31-38.
60. Wright, K. E., and M. J. Buchmeier. 1991. Antiviral antibodies attenuate T-cell-mediated immunopathology following acute lymphocytic choriomeningitis virus infection. J. Virol. 65:3001-3006.
61. Wright, T. L., and J. Y. N. Lau. 1993. Clinical aspects of hepatitis B virus infection. Lancet 342:1340-1344.
62. Zinkernagel, R. M., T. P. Leist, H. Hengartner, and A. Althage. 1985. Susceptibility to lymphocytic choriomeningitis virus isolates correlates directly with early and high cytotoxic T cell activity, as well as with footpad swelling reaction, and all three are regulated by H-2D. J. Exp. Med. 162:2125-2141.